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Understanding the molecular mechanism by which pluripotency is maintained in human embryonic stem
cells (hESC) is important for the development of improved methods to derive, culture and differentiate
these into cells of potential therapeutic use. Large-scale transcriptional comparison of the hES-NCL1 line
derived from a day 8 embryo with H1 line derived from a day 5 embryo (WiCell Inc.) showed that only
0.52% of the transcripts analysed varied significantly between the two cell lines. This is within the variability
range that has been reported when hESC derived from days 5–6 embryos have been compared with each
other. This implies that transcriptional differences between the cell lines are likely to reflect their genetic
profile rather than the embryonic stage from which they were derived. Bioinformatic analysis of expression
changes observed when these cells were induced to differentiate as embryoid bodies suggested that quite a
few of the downregulated genes were components of signal transduction networks. Subsequent analysis
using western blotting, flow cytometry and antibody arrays implicated components of the PI3K/AKT
kinase, MAPK/ERK and NFkb pathways and confirmed that these components are decreased upon
differentiation. Disruption of these pathways in isolation using specific inhibitors resulted in loss of pluri-
potency and/or loss of viability suggesting the importance of such signalling pathways in embryonic stem
cell maintenance.
INTRODUCTION
Human embryonic stem cells (hESC) hold great promise for
understanding early human embryonic development and
generating clinically useful cell lines (1,2). In view of this a
great deal of effort is focused on experiments aimed at
improving culture conditions (3), generating new hESC lines
suitable for clinical purposes (4), genetic manipulation (5,6)
and differentiation regimes to produce human cells suitable
for transplantation and drug testing (7,8). To date, more than
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300 hESC lines have been derived worldwide; however, only a
handful of these have been extensively characterized using
large-scale transcriptomic approaches. These techniques
have shown that similar to murine ESC (mESC), hESC
express some of the classical markers of pluripotent stem
cell lines such as OCT4, NANOG, alkaline phosphatase
(AP) and high levels of telomerase activity (1). However,
there are many notable differences between human and
mouse ESC in both morphological and behavioral character-
istics such as colony thickness, shape and population
doubling time (9). The expression of cell surface marker
proteins differs considerably (10) and large-scale transcrip-
tional profiling studies undertaken by a number of groups
reveal that 10% of the genes showing significant expression
changes between mouse and human ESC are involved in
oxidative phosphorylation, suggesting that mESC have a
higher ability to generate ATP and higher metabolic rate
powered by mitochondrial oxidation (11). Although
leukaemia inhibitory factor (LIF) modulated through gp130
signalling and the JAK/STAT pathway is sufficient for the
maintenance of undifferentiated mESC, it cannot prevent the
spontaneous differentiation of hESC (12). In addition,
hESC unlike mESC can spontaneously differentiate to tro-
phectoderm (13). These differences between mouse and
human cells suggest that although the same pluripotentiality
genes are expressed in both mouse and human ESC, their
function and downstream signalling pathways may differ
between the two species. This highlights the importance and
necessity of studying signalling pathways that underline the
maintenance of pluripotency and viability in hESC given the
potential importance of stem cell therapies in therapeutic
medicine.
Recent publications detailing transcriptional profiling of
several hESC lines (14–23) have shown that there are
common genes expressed in several cell lines. However,
each cell line possesses a unique expression signature which
may reflect either the genetic profile of the embryo from
which they have been derived or the differences in conditions
used either for the derivation, culture or cryopreservation of
cell lines in different laboratories (22,23). The differences in
gene expression might also be a function of the developmental
stage of the embryo from which the hESC lines are derived;
however, this hypothesis has been difficult to test because
the majority of the hESC lines were derived from days 5–6
blastocysts. More recently, derivation of cell lines from
morulae has been described (24), and 2 years ago, our group
was able to isolate a new hESC line, hES-NCL1 from day 8
human embryos using a novel three-step culture condition
approach (25). This cell line gives us a unique ability to
assess whether the developmental stage of the embryo
affects the transcriptional profile of the hESC lines. In
this manuscript, we report for the first time that the develop-
mental stage of the embryo does not enhance the trans-
criptional differences already reported between different cell
lines and therefore these are more likely to be due to
genetic profile of the embryo from which they are derived.
We also highlight three signalling pathways, namely PI3K/
AKT, RAS/MAPK and NFkb, and indicate that they are
crucial for the maintenance of pluripotency and/or viability
in hESC.
RESULTS
hES-NCL1 cell line shows similar phenotypic and
transcriptional characteristics to H1 cells
Recently, we reported the derivation of a new hESC line,
hES-NCL1, from day 8 embryos, using novel three-step
culture conditions (25). The majority of the hESC lines
reported to date have been derived from days 5 and 6
embryos. In view of this, we set out to compare our cell line
hES-NCL1 with the H1 line available from WiCell Inc.
(Madison, USA) and to determine whether these cells
derived from day 8 embryos showed any phenotypic or signifi-
cant transcriptional difference to cells derived from earlier
embryos (such as the H1 line). Both of these cell lines have
been extensively characterized in vitro and shown to contrib-
ute to teratoma formation in vivo (1,25). We cultured the two
cell lines under the same conditions (see Materials and
Methods) and by the same investigator continuously up to
passage 70. We first examined the expression of cell surface
markers (TRA-1-60, TRA-1-81, SSEA-3, 4, 1, CD117 and
CD135) by flow cytometry at passages 38 (Fig. 1A), 56
(data not shown) and 70. In all cases, we observed very
similar marker expression for both cell lines. No gross karyo-
typic abnormalities were found up to 70 continuous passages
in culture (Fig. 1B). Both of the cell lines expressed markers
such as OCT4, NANOG, REX1 and TERT at both passages
38 (data not shown) and 70 (Fig. 1C) as shown by the
reverse transcription assay. As this method is only semi-
quantitative and does not reflect properly the levels of gene
expression between the two cell lines, we investigated their
relative expression using microarray technology as outlined
in Expression profiling of hES-NCL1 and H1: comparison
with other hESC lines. This indicated that there was no signifi-
cant difference in the expression levels of NANOG, OCT4,
TERT and REX1 between the two cell lines (Fig. 1D; in all
cases, P . 0.5). This result was confirmed by real-time
reverse transcription (RT)–PCR analysis (data not shown).
To assess the growth rate of the two cell lines, hESC colo-
nies were disrupted to single cells by digestion with accutase,
which results in much higher cell viability compared with
trypsin digestion (our own unpublished data). Fifty thousand
cells were plated in triplicate on fresh mitotically inactivated
mouse embryonic fibroblasts and allowed to grow for 5 days
before being subjected to the digestion procedure and
counted again. This was repeated for five passages and the
results indicate that the average population doubling time for
the hES-NCL1 line was 43.5 h and that for the H1 line was
44.2 h.
To assess the degree of variability in differentiation
capacity, we removed colonies of both hESC lines from the
feeder cells and cultured them in suspension as embryoid
bodies (EBs) for up to 15 days. Differentiation was confirmed
by flow cytometry for the hESC-specific cell surface marker,
TRA-1-60 which showed significant downregulation during
the differentiation of hESC (74% of the hESC stained with
TRA-1-60) to EBs (6.05 and 4.11% of the cells remained
TRA-160-positive after 7 and 14 days of differentiation,
respectively; data are presented as an average of both cell
lines). Samples of cells were removed at days 0, 5, 10 and
15 and subjected to quantitative real-time RT–PCR for
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markers of pluripotency (GDF3), endoderm (AFP), mesoderm
(KDR) and ectoderm (PAX6; Fig. 1E). As reported for other
cell lines (14), both lines used in the study differentiated
into cells that expressed markers indicative of the three
germ layers. However, there were some differences in the
expression levels of the same gene between the two cell
lines studies at identical time points which might indicate
their preference for differentiation towards a specific lineage.
Most importantly, changes in marker expression can reflect
the level of spontaneous differentiation occurring at different
rate in different hESC lines. Although we have tried to mini-
mize such differences between the two cell lines (Fig. 1A), the
real-time RT–PCR is a sensitive technique, and hence minor
changes in the level of spontaneous differentiation can result
in rather major changes in gene expression during the
differentiation of these two cell lines.
Expression profiling of hES-NCL1 and H1:
comparison with other hESC lines
The gene expression pattern in both cell lines was assessed by
hybridization of their respective mRNA output at passages
38–45 to the human U133 Plus 2.0 array which represents a
coverage of 47 000 transcripts and variants including 38 500
well-characterized human genes and ESTs. We only con-
sidered a gene to be present in each cell line if that gene
received a present call in three independent samples and the
detection P-value was less than 0.000244. Twenty-two
thousand two hundred and thirty-two transcripts (47.3%)
were found to be present in the H1 cell line and 21 683
transcripts (46.13%) were detected in the hES-NCL1 line.
To identify genes that were present in both cell lines, a
Venn diagram was drawn using Genespring (Fig. 2A) and
this showed that 20 382 transcripts were present in both cell
lines (43.3%), whereas 1850 (3.9%) transcripts were present
in H1 but not in hES-NCL1 and 1301 (2.7%) transcripts
were present in hES-NCL1 but not in H1. Abeyta et al. (14)
reported that 52% of the total transcripts were shared by all
the three cell lines they analysed (H9, HSF-1 and HSF-6)
and this is slightly higher than that we have observed
(43.3%); however, the differences might relate to stringency
of criteria chosen because ‘present and marginal’ expression
was included in their list, whereas ‘present only’ was the
selection criterion in our study. Most importantly, this can
be dependent on the number of cell lines being compared.
To verify this, we extended our analysis to the four
hESC cell lines of University of Helsinki (FES21,
FES22, FES29 and FES30) and three hESC cell lines of
Karolinska University (HS181, HS 235, HS237) kindly
provided to us by Dr Heli Skottman (23). A comparative
analysis of all nine cell lines indicated that less transcripts
were shared between all of them (27.8% of total transcripts,
Fig. 2B). This highlights the need to compare larger
number of cell lines, especially if new ESC biomarkers are
sought.
A number of groups have tried to identify genes that can
be used as hESC markers (22,23). This approach has resulted
in several gene lists which show increasing discrepancies
from one publication to the next (22,23). The variability in
the results probably reflects the differences in the technical
Figure 1. Phenotypic and transcriptional comparison of the hES-NCL1 line
with H1. (A) Cell surface staining of the two hESC lines at passage 38
(shown in black) and at passage 70 (shown in red). The data represent the
mean+ SEM performed on three independent measurements. (B) Karyotypic
analysis of the two hESC lines at passage 70. (C) RT–PCR analysis of the two
hESC lines for the expression of OCT4, REX1, NANOG and TERT. GAPDH is
used as a normalizing control. ‘þ’ indicates the presence of reverse transcrip-
tase and ‘2’ the lack of the enzyme. (D) Expression analysis of NANOG,
OCT4, REX1 and TERT in hES-NCL1 and H1. The data are plotted as
average of three normalized ratios obtained after hybridization of three separ-
ate hES-NCL1 and H1 samples to U133 Plus 2.0 array (Affymetrix). (E) Real-
time RT–PCR analysis for pluripotency markers (GDF3), endoderm markers
(AFP), mesoderm markers (KDR) and ectodermal marker (PAX6) during
differentiation of hESC to EBs. For each gene, the value for the hESC was
set to 1 and all other values were calculated with respect to this.
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approach used for such large-scale expression studies (22),
differences in culture conditions (23), the number of repli-
cates and the stringency of statistical analysis as well as
the availability of raw data from a large number of hESC
lines (26). Because the number of transcripts shared
between different cell lines is partly dependent on the
number of hESC lines being compared, we hypothesized
that more specific hESC biomarkers can be identified by
increasing the number of cell lines being compared. To
investigate this, we initially compared the H1 and
hES-NCL1 lines with the differentiated progeny derived
from each line to identify hESC-enriched genes. The com-
parison level analysis of each hESC line to non-lineage
differentiated reference samples (these were differentiated
progeny from hESC lines obtained after 3 weeks) defined a
gene as significantly enriched in hESC if the average
signal fold change (FC) between the hESC and the reference
sample was larger than two and the gene in hESC sample
was present. This analysis identified 1232 transcripts that
were enriched in both H1 and hES-NCL1 compared with
more differentiated progeny (Fig. 2C). Addition of another
seven hESC lines (FES21, FES22, FES29, FES30, HS181,
HS235 and HS237) to this comparison reduced the list of
ESC-specific transcripts to 235 (representing 206 genes and
ESTs; Fig. 2C, and for a complete list, see Supplementary
Material, Table S1), thereby highlighting the validity of
our hypothesis. Most importantly, the list of hESC-specific
genes comprised several well-known hESC markers already
identified in other studies such as OCT4, NANOG, CD24,
GDF3, TDGF1, TERF1, GABRB3, POLR3G, LECT1,
DPPA4, GALANIN, DNMT3B and LIN28 (14–24,34). In
addition to the hESC-enriched transcripts, we were also
interested to identify highly expressed genes in all nine
cell lines and any potential overlaps between the two popu-
lations. To select highly expressed transcripts in both cell
lines, the Genespring feature called ‘filter on expression
level’ was used by applying a minimum cut-off point of
110 to normalized data from the nine cell lines. A list of
117 transcripts representing 85 genes and ESTs (Supplemen-
tary Material, Table S2) was identified. From this analysis,
we observed that the most abundant class of transcripts
expressed in both cell lines were ribosomal proteins followed
by transcription factors and nucleic acid binding proteins and
protein processing and trafficking systems, which is perhaps
indicative of a high rate of protein turnover in hESC. This
is in accordance with other studies which have used SAGE
and MPSS as a technique for identification of genes highly
expressed in hESC lines (11,20). Comparison of the 85
highly expressed genes and ESTs with the 206
hESC-enriched genes and ESTs showed that only two
genes were shared between them (HDCMA18P and
CACNA2D3). Investigation of several databases including
NetAffix, NCBI, Unigene, etc. revealed that HDCMA18P is
likely to be involved in RNA binding and processing,
whereas the CACNA2D3 (calcium channel voltage-dependent
alpha2/delta3) is likely to mediate the influx of calcium ions
into the cell upon membrane polarization. Both of the genes
are novel, therefore further detailed investigations are needed
before any conclusion can be reached regarding their func-
tion in hESC.
Figure 2. Expression profiling of hES-NCL1 and H1. (A) Venn diagram
showing the transcripts present in both cell lines as well as transcripts
which were specific to one of the cell lines only. (B) Venn diagram
showing the transcripts present in all nine hESC lines (H1, hES-NCL1,
FES21, FES22, FES29, FES30, HS181, HS235 and HS237). Genes that
were present in FES21, FES22, FES29, FES30, HS181, HS235 and HS237
were selected by performing stepwise Venn diagram analysis for every three
cell lines. (C) Venn diagram showing the hESC-enriched transcripts compared
with non-lineage differentiated cells. The circle in the left represents the tran-
scripts that are enriched in hES-NCL1 compared with day 21 EBs, the circle in
the right represents the transcripts that are enriched in H1 compared with day
21 EBs and the circle in the bottom represents the transcripts that are enriched
in pooled hESC (HS181, HS235, HS237, FES21, FES22, FES29, FES30)
compared with day 21 differentiated progeny.
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Other key pluripotency factors such as OCT4, REX1,
NANOG, LIN28, CD24 and TERT are not represented among
the highly expressed transcripts. This shows that highly
expressed genes, although being part of the molecular signa-
ture for the hESC, will not necessarily be part of the functional
machinery of hESC that can be exploited further for directing
their differentiation.
Identification of most changed transcripts between
the two cell lines
Because the hES-NCL1 line was derived from day 8 blasto-
cysts, we were interested to determine whether it showed sig-
nificant changes in gene expression from the H1 line which is
derived from day 5 embryos. Using the Genespring software,
we identified genes that were unique to H1, unique to
hES-NCL1 or differentially expressed between the two cell
lines. To identify the genes unique to each cell line, we fol-
lowed the criteria that the gene had to be present in three
out of the three replicates for the target cell line and absent
in three out of the three replicates for the reference cell line.
This identified 61 genes present in H1 (0.27% of all transcripts
present) but completely absent in hES-NCL1 (Supplementary
Material, Table S3) and 49 genes which were present only in
hES-NCL1 (0.22% of all transcripts present; Supplementary
Material, Table S3). The differential expression of six of the
uniquely expressed candidates was confirmed by real-time
PCR analysis (Fig. 3B). The most differentially expressed
transcripts were of various natures: about one-third is as yet
uncharacterized on a functional level and more than 10% are
involved in DNA transcription (Supplementary Material,
Table S3). The H1 and hES-NCL1 lines have different
karyotype (i.e. H1 is male, NCL-1 is female; Fig. 1B), and
this might contribute to their unique expression pattern.
However, this does not seem to be a major factor, because
only 3/61 genes that are unique to H1 are located on the Y
chromosome (Fig. 3A). It is highly likely that these genes
do not represent important regulators of pluripotency or differ-
entiation because both cell lines are capable of differentiating
into multiple cell lineages. It is interesting, however, that the
nine genes we investigated by real-time RT–PCR not only
show changes in expression between the two hESC lines,
but also between each line and the embryonic carcinoma
cell line (NTera2-SP.12) which was used as a positive
control (Fig. 3B). Although the embryonic carcinoma cells
show chromosomal abnormalities, they do retain the capacity
to differentiate into several lineages and express most of
the genes normally found in hESC lines albeit not neces-
sarily at exactly the same level. This again suggests that
variability in the expression of the candidate genes we have
selected through the microarray analysis is unlikely to affect
the pluripotency or differentiation capacity of these cells;
however, genes which differentially expressed between the
two cell lines might be useful as a ‘fingerprint’ for each
cell line.
Using the Genespring software, we also investigated genes
that consistently show more than 2-fold expression changes
between the two cell lines in three replica experiments. A
stringent P-value was chosen to ensure significant differences
between the two cell lines. Surprisingly, we found that only
six genes which comprise 0.03% of the transcripts present in
the two cell lines (Fig. 3A) fell into this category. The differ-
ential expression of three of these candidates (SLC1A6,
PDCD6 and MNS1) was also confirmed by real-time RT–
PCR (Fig. 3B). These results are very similar to a study pub-
lished by Carpenter et al. (21), which showed that only three
genes out of 2802 cDNA clones showed differential
expression between four hESC lines (H1, H7, H9 and H14).
The number of the unique genes that we found for each
hESC line together with the genes that are differentially
expressed between them is significantly lower than what has
been previously reported for other hESC lines such
as HSF-1, HSF-6 and H9 (14) or HS181, HS235, HS237,
FES21, FES22, FES29 and FES30 (23). These differences
could be attributed to changes in number of replicates used
in the gene expression studies [two replicates were used by
Skottman et al. (23)], the number of hESC lines being com-
pared or the stringency of gene selection criteria [present
and marginal genes were used by Abeyta et al. (14)]. Our
own unpublished data suggested that both the increase in
number of replicates and selection of only genes deemed to
be present reduced significantly the number of genes
considered unique or differentially expressed for each cell
line (for example, comparison of the two cell lines using the
criteria of present or marginal in one out of three samples
for each hESC line increased the number of genes that
showed two or more FC to 64).
In summary, the percentage of genes that are differentially
expressed between the hES-NCL1 cell line derived from day
8 embryos to H1 derived from day 5 embryos is only
0.52%. This is within the variability limits described for
ESC derived from days 5–6 embryos such as HSF-1, HSF-6
and H9 (2.4–4.5%) (14) and HS181, HS235, HS237,
FES21, FES22, FES29 and FES30 (2.1–3.6%) (23).
Large-scale gene expression studies in lymphoblastoid cells
lines derived from unrelated individuals have shown that up
to 5% of the genes can vary from one individual to another
(27). In view of this, we would like to suggest that changes
in the gene expression between the two cell lines we have ana-
lysed are likely to be due to the changes in the genetic profile
of the embryo rather than the developmental stage of the
blastocyst from where they were derived. To verify this
further, one will have to compare directly gene expression
patterns between ICMs dissected from different stages of the
blastocyst’s development and hESC lines derived from
earlier embryos such as morulae. This work is currently
progressing within our group.
Identification of new hESC markers
One of our aims in this investigation was to identify new
hESC markers; therefore, we collected RNA samples from
days 6, 10, 14 and 21 EBs from the hES-NCL1 line and
hybridized these samples to the human U133 Plus 2.0 array.
Using the Genespring software and a stringent selection
criterion of at least 4-fold downregulation between the
hES-NCL1 line and each group of EBs collected at different
days (days 6, 10, 14 and 21, respectively), four groups of
transcripts were selected (Fig. 4A). A Venn diagram was
drawn to identify the set of transcripts that were common to
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all the four subsets and indicated genes that were expressed in
the hES-NCL1 but were downregulated 4-fold or more at
all differentiation time points examined. One hundred and
eighteen transcripts which represented 105 genes were
identified and among those the major category comprised
uncharacterized transcripts and genes involved in signalling
pathways (Fig. 4B, and for a complete list, see Supplementary
Material, Table S4).
Figure 3. Identification ofmost changed transcripts between the two cell lines. (A) Genes that showmore than 2-fold change in expression betweenH1 and hES-NCL1
cell lines. Change in P-value is calculated using the Wilcoxon’s signed-rank test and ranges from 0.0 to 1.0 and provides a measure of the likelihood of change and
direction. P-values close to 0.0 indicate likelihood for an increase in transcript expression level in the experiment array (H1) compared with the baseline (hES-NCL1),
whereas P-values close to 1.0 indicate likelihood for a decrease in transcript expression in the experiment array (H1) compared with the baseline (hES-NCL1).
(B) Real-time RT–PCR analysis for three genes that show differential expression between the two cell lines (MNS1, SLC1A6, PDCD6), three genes that are
unique to H1 (GSTT1, PCDHB6, ZNF224) and three genes that are unique to hES-NCL1 (TXNRD3, XRCC4, ZNF441). A sample of embryonic carcinoma cells
(NTera2-SP.12) was used as a positive control and normalized to 1 in each real time RT–PCR experiment. All other values were calculated with respect to this.
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It is interesting to note that 12.38% of the identified
transcripts have been already associated with maintenance of
pluripotency in human and mouse ESC previously (OCT4,
NANOG, TDGF1, GDF3; Supplementary Material,
Table S4) or selected on the basis of higher expression in
ESC versus EBs (GAL, SEMA6A, LECT1, FLJ10884,
POLR3G, LGALS1, GABRB3, TFRC, TERF1, DPPA4,
DNMT3B, NODAL, HESX, PRDM14) by other groups
(14–23). Preliminary studies in murine and human ESC
have already revealed a role for DNMT3B, NODAL,
POLR3G and GAL in cell growth, viability and maintenance
of pluripotency (28–35). In view of the published evidence
and availability of commercial antibodies for some of
these factors, we decided to investigate in further detail the
expression and localization of LGALS1, TFRC and
GABRB3 in hESC (Fig. 4C). LGALS1 also known as galec-
tin1 can restrict carcinoma cell growth via suppression of
RAS/MEK/ERK signalling pathway and induction of p21
and p27 transcription (36). This evidence seems to suggest
that the high and selective expression of LGALS1 in hESC
is required for maintaining ESC homeostasis and perhaps pre-
venting a tumorigeneic expansion; however, further work is
Figure 4. Identification of new hESC markers. (A) Identification of transcripts that are enriched in hESC and downregulated at least 4-fold compared with EBs
collected at days 6, 10, 14 and 21. The Venn diagram on the left shows the selection of 245 common transcripts between the three groups selected previously on
the basis of at least 4-fold downregulation from hES-NCL1 to EBs at days 6, 10 and 14, respectively. The Venn diagram on the right shows the cross comparison
of these 245 transcripts (Venn diagram on the left) to genes present in all three replicates of hES-NCL1 and the group of transcripts that show at least 4-fold
downregulation from hES-NCL1 to day 21 EBs. (B) Pie chart analysis showing the functional characterization of 105 genes that are enriched in hESC compared
with EBs. (C) Immunocytochemistry for LGALS1, TFRC and GABRB3 in hES-NCL1 (similar images were obtained in the H1 cell line, data not shown).
Immunofluorescence images for each antibody are shown in the middle panels. Bright field images are shown on the left panels and cell nuclei by DAPI staining
are shown in the right panels. (D) Flow cytometry analysis for the expression of TFRC and TRA1-60 in hES-NCL1 and day 14 EBs (the same results were
obtained using the H1 cell line, data not shown).
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needed to verify this suggestion. The transferrin receptor,
TFRC, acts normally as a gatekeeper for maintaining iron
homeostasis by mediating endocytosis of its ligand, iron-
loaded transferrin, and high expression of this receptor has
been observed in human mesenchymal stem cells and mESC
(37,38). However, ablation of this gene in murine embryos
suggests that transferrin and its receptor TFRC are mostly
required for development of haematopoietic cells such as
erythrocytes and lymphocytes but they are not essential for
development of other tissues (38,39). The human GABA A
receptor subunit beta 3 (GABRB3) was found to be an
imprinted gene and a possible candidate for Prader–Willi
syndrome (40), and the downregulation of its paternal allele
in murine embryos results in a neurodevelopmental disorder
which mimics Angelman syndrome (41); however, no
functional role in stem cells has been described so far. A
recent paper described the successful use of g-aminobutyric
acid and pipecolic acid which enhances GABA A receptor
responses together with FGF2, LiCl2 and TGFb in
defined medium to grow and derive new hESC lines (42).
This was based on previous reports which indicated that
GABA can stimulate proliferation of both neural and
non-neural tissue (43) and microarray results similar to the
ones presented here (15). Expression differences for these
three genes were examined by flow cytometry (both
intra and extracellular, data not shown) and immunocyto-
chemistry (Fig. 4C). This indicated that TFRC is the only
marker with cell surface expression; therefore, we compared
TFRC expression with that of TRA-1-60 in hESC and
day 14 EBs by flow (Fig. 4D). This analysis showed that
4% of the cells maintained the expression of TFRC after
14 days of differentiation; however, this was also the
case with TRA-1-60 staining, suggesting that TFRC may
serve as a new marker to distinguish hESC from cells
present in EBs.
Signalling pathways in hESC
The second largest category of transcripts enriched in hESC
similar comprised the genes involved in signalling pathways
(Figs 4B and 5A). Interestingly, a significant number of
those candidates fell within three major signalling categories
belonging to the RAS/MAPK/ERK signalling pathway
(G3BP, RASAL2, SOS1 and ITGB1BIP3), the PI3K/AKT
(PI3KCB and PTEN) and NFkb signalling (LCK, PELLINO1
and TNSF11).
The RAS/MAPK/ERK, PI3K/AKT and NFkb signalling
pathways identified above represent novel pathways that
have not been thoroughly investigated in hESC. These
pathways are very complex and involve a large number of
components, and to facilitate the unfamiliar reader, we have
outlined them schematically in Figure 5B.
RAS is a small GTPase responsible for transducing signals
from a vast array of receptor tyrosine kinases and other
receptors. RAS itself is regulated by GTPase-activating
proteins (GAPs), which alternate signalling. RAS GAP trans-
duces signals downstream of RAS in a MAPK-dependent
manner (Fig. 5B, top panel). RAF serine/threonine protein
kinases are considered to be the primary RAS effectors and
are normally localized in the cytosol in inactive form.
However, c-RAF (also known as RAF1) associates with
RAS at the plasma membrane after growth factor-induced
RAS guanine nucleotide exchange and its activation, which
links a series of phosphorylation and changes in subcellular
localization, links RAS to mitogen and extracellular-regulated
kinase (MEK1/2) and MAPK. RAF directly phosphorylates
and activates the protein kinase MEK1/2 which in turn
phosphorylates and activates MAPK/ERK1 and MAPK/
ERK2 (Fig. 5B, top panel). Activated MAPK/ERKs are then
translocated from the cytoplasm to the nucleus where they
activate nuclear transcription factors leading to changes in
gene expression (Fig. 5B, top panel). Pi3K enzymes are
normally regulated by growth factors and serve to phosphory-
late phospholipids at the plasma membrane (Fig. 5B, bottom
panel). Activated PI3K phosphorylates PIP2 and generates
PIP3 which acts as a second messenger. AKT interacts with
PIP3 and subsequently translocates to the plasma membrane.
AKT also referred as PKB plays a critical role in controlling
the balance between survival and apoptosis (Fig. 5B,
bottom panel) and is activated by phospholipid binding and
activation loop phosphorylation at threonine 308 by PDK1
and phosphorylation at the C-terminus at serine 473. It is
inactivated by PTEN phosphatase. AKT promotes cell
survival by inhibiting apoptosis through its ability to phos-
phorylate and inactivate several target genes such as BAD,
c-RAF and caspase-9 (Fig. 5B, bottom panel). In addition, it
regulates glycogen synthesis through phosphorylation
and inactivation of GSK3b and GSK3a. Activation of
AKT survival signalling pathways leads to phosphorylation
of Ikb, the cytoplasmic inhibitor of nuclear factor kb
(NFkb). Phosphorylation of Ikb initiates proteasome-
dependent degradation and allows NFkb to enter the nucleus
and regulate NFkb-dependent gene expression (Fig. 5B,
bottom panel).
Ras-GTPase-activating protein, SH3-domain-binding
protein (G3BP1), was downregulated more than 4-fold
during the differentiation of hESC (Fig. 5A). G3BP1 binds
to the SH3 domain of Ras GAP and is shown to act as a
Ras effector in breast cancer cell lines (44). Complete ablation
of this gene in mouse results in embryonic lethality indicating
an important role during embryonic development (45). Other
activators of the pathway, such as RASAL2 and SOS1,
which are guanine nucleotide exchange factors are also
downregulated at the transcriptional level during differen-
tiation, implying a greater role for RAS/MAPK signalling in
hESC (Fig. 5A). We observed that one of the integrin b1
binding proteins, ITGB1BP3, which has been shown to
affect laminin deposition and myogenic differentiation
(46,47) is expressed at much higher levels in ESC compared
with EBs (Fig. 5A). We investigated other members of the
RAS/MAPK/ERK signalling pathway (Supplementary
Material, Table S5) and noticed that several other components
(MAP4K1, MAP2K6, MAP3K7, MAP4K3, RAF1, MAPK13,
MAPK9, MAPK6, MAPK1/ERK1, MAP2K1, KRAS, MAP3K4,
NRAS, BRAF) were transcriptionally downregulated during the
differentiation process, albeit less than 4-fold. Taken together
these insights acquired from the transcriptional study suggest a
role for the RAS/MAPK/ERK signalling pathway in hESC.
Our transcriptional data also suggested a downregulation of
several components of the NFkb signalling pathway such as
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Figure 5. Expression of main components involved in signalling pathways in hESC. (A) Expression of transcripts involved in signalling pathway that are
enriched in hESC compared with EBs. (B) Schematic presentation of three signalling pathways: RAS/MAPK/ERK (top panel), PI3K/AKT kinase and NFkb
(bottom panel). (C) Immunocytochemistry for components of RAS/MAPK signalling pathways in hESC. Immunofluorescence images for each antibody are
shown in the middle panels. Bright field images are shown on the left panels and the overlap of cell nuclei by DAPI staining (in blue) and antibody staining
(in green) is shown in the right panels. (D) Immunocytochemistry for components of PI3K/AKT signalling pathways in hESC. Immunofluorescence images
for each antibody are shown in the middle panels. Bright field images are shown on the left panels and the overlap of cell nuclei by DAPI staining (in blue)
and antibody staining (in green) is shown in the right panels. (E) Immunocytochemistry for components of NFkb signalling pathways in hESC. Immunofluor-
escence images for each antibody are shown in the middle panels. Bright field images are shown on the left panels and the overlap of cell nuclei by DAPI staining
(in blue) and antibody staining (in green) is shown in the right panels. (F) Top panel: flow cytometry analysis for various components of RAS/MAPK/ERK
signalling pathway in hESC (hES-NCL1 line) and day 14 EBs (identical results were obtained with H1 line, therefore this data is not shown). Bottom panel:
western blot analysis of several components of MAPK/ERK signalling pathways in hESC (H1 line) and day 14 EBs; GAPDH is used as a loading control.
(G) Flow cytometry analysis for various components of PI3K/AKT signalling pathway in hESC (hES-NCL1 line) and day14 EBs (identical results were obtained
with H1, therefore this data is not shown). (H) Flow cytometry analysis for various components of NFkb signalling pathway in hESC (hES-NCL1 line) and
day14 EBs (identical results were obtained with H1, therefore this data is not shown). (I) Hybridization of hESC (labelled with Cy3) and day 14 EB extracts
(labelled with Cy5) to Panorama antibody cell signalling assays for various components of RAS/MAPK/ERK, PI3K/AKT and NFkb signalling pathways. A ratio
.1.0 indicates higher expression in hESC than EBs and ratio ,1.0 indicates higher expression in EBs compared with hESC.
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LCK, PELLINO1 and TNFS11/ RANKL (Fig. 5A). LCK, a
lymphocyte-specific tyrosine kinase, (Src kinase) required
for the activation of the NFkb signalling pathway (47) has
been shown to be downregulated during mESC differentiation
(48). In addition, the product of another candidate gene,
PELLINO1, identified in this screen is required for NFkb
activation, probably through interactions with IRAK and
tumour necrosis factor receptor associated factor TRAF6
(49). Other members of these signalling pathways were
either absent (TLRs) or slightly upregulated (Supplementary
Material, Table S5). However, as for most of the signalling
pathways, phosphorylation/translocation of key components
as well as abundance of ligands/activators plays the most
important role. In view of these, we looked carefully at
NAK (NFkb activating enzyme; Supplementary Material,
Table S5) which showed less than 4-fold downregulation
during the differentiation process and the IKBK1 (which
enhances the stability of Ikks and therefore downregulates
NFkb activity) which was absent in both hESC lines and
upregulated during the differentiation process (Supplementary
Material, Table S5). Most importantly, the receptor activator
of nuclear factor (NFkb) ligand (RANKL/TNFS11) which is
also enriched in hESC compared with EBs has been shown
to be translationally regulated by PDK1 via the PI3K/AKT
pathway suggesting a potential link between these two path-
ways (50,51). Interestingly, PDK1 activates NFkb signalling
by phosphorylating IKKb which leads to its degradation and
therefore allowing NFkb p65 to enter the nucleus (51,52).
Figure 5. Continued.
Human Molecular Genetics, 2006, Vol. 15, No. 11 1903
AKT has also been shown to be involved in transactivation of
p65 and subsequent NFkb-dependent transcription (52). These
data seem to suggest an intrinsic link between the NFkb and
PI3K/AKT signalling pathways in other cell lines; however,
this has not been explored previously in hESC. Of interest is
the finding that PI3K/AKT pathway has been shown to be
important for the maintenance of pluripotency in mESC
(53), whereas FGF2 which is necessary for hESC growth acti-
vates ERK signalling (54–56). In view of this, it is important
to investigate whether FGF2 signalling activates PI3K/AKT
pathway in addition to MAPK/ERK signalling in hESC.
Although our transcriptional data suggest that the three
selected pathways, PI3K/AKT, NFkb and MAPK signalling,
might be important for proliferation and maintenance of pluri-
potency in hESC, in-depth studies to investigate the role of
these pathways in hESC and potential links between them
have not been carried out as yet. We investigated the
expression of some crucial components of these three path-
ways in hESC and changes during their differentiation to
EBs. Immunocytochemistry on both H1 and hES-NCL1 on
various components of these three signalling pathways (see
Fig. 5C, D and E for RAS/MAPK, PI3K/AKT and NFkb sig-
nalling pathways, respectively) demonstrated cytoplasmic/cell
membrane localization for the phosphorylated form FRS2a
and nuclear localization for phospho-ELK1 and c-MYC
(Fig. 5C). The phosphorylated form of c-RAF serine 338 as
well as GAB1, SOS1 and GRB2 showed both nuclear
and cytoplasmic/cell membrane localization (Fig. 5C).
Most of the components of the PI3K/AKT pathway
(phospho-GSK3b, phospho-c-RAF serine 259, phospho-PDK1
and phospho-AKT threonine 308) showed cytoplasmic/cell
membrane localization and a few (unphosphorylated AKT,
phospho-AKT serine 308 and phospho-PTEN) displayed
both nuclear and cytoplasmic/cell membrane localization
(Fig. 5D). In contrast, all the tested components of the
NFkb pathway showed nuclear localization with the exception
of TNSF11 which showed some additional spotty expression
in the cytoplasm (Fig. 5E). We were unable to detect the
expression of phospho-MEK1/2, phospho-ERK1/2 (also
known as p44/42) and phospho-90 RSK (Fig. 5B) which
suggests that they might be expressed at lower levels. To
improve the detection sensitivity and assess changes
between hESC and EBs, we carried out flow cytometry analy-
sis for all the components involved in these pathways for
which commercial antibodies were available (Fig. 5F–H).
This showed that the key components of the RAS/MAPK/
ERK pathway (phospho-c-RAF serine 338, phospho-MEK1/2,
phospho-ERK1/2, phospho-ELK1, phospho-c-MYC and
phospho-p90; Fig. 5F), PI3K/AKT pathway (phospho-
PDK1, phospho-PTEN, phospho-AKT serine 473 and
phospho-AKT threonine 308, phospho-c-RAF serine 259;
Fig. 5G) and NFkb pathway (phospho-65 and TNFS11;
Fig. 5H) were all downregulated during differentiation. For
some of the MAPK/ERK signalling pathway, this downregula-
tion was confirmed by western blotting (Fig. 5F, lower panel).
To confirm our initial flow cytometry results, we also took
advantage of the panorama Ab microarray for cell signalling
components where a good percentage of the antibodies of
interest are spotted in duplicate on nitrocellulose filters. We
hybridized hESC and day 14 EB cell extract to those arrays
and calculated the ratio of hESC/EB for each protein of inter-
est (Fig. 5I). This analysis confirmed our flow cytometry
results and suggested that hESC expressed higher levels of
key components of the MAPK/ERK signalling pathways
(phospho-ERK1/2, phospho-c-RAF and phospho-c-MYC) as
well as the PI3K/AKT (phospho-AKT serine 473 and
phospho-AKT threonine 308) and NFkb pathways (p65 and
NAK- NFkb-activating kinase). These results were confirmed
by dye reversal experiment (Supplementary Material, Fig. S1).
In both experiments, we observed that hESC/EB ratio for
GRB2 was different in each of the cell lines. Investigation
of the normalized values for GRB2 in the two cell lines
showed very similar expression (Supplementary Material,
Table S5); however, different expression was observed in
day 14 EBs obtained from the two different hESC lines.
This transcriptional difference could account for rather differ-
ent hESC/EB ratios in the two cell lines.
FGF, BMP/TGFb and WNT signalling have been impli-
cated in the maintenance of pluripotency in human ESC
(54–56). In view of these, we investigated our microarray
data for the expression of main components of these signalling
pathways. A close investigation of the FGF2 signalling
pathway indicated an abrupt downregulation of FGF2
during the differentiation process as well as two of the FGF
target genes, c-FOS and c-KIT (Supplementary Material,
Table S5). This is in accordance with other published findings
which demonstrate a crucial role for FGF2 in maintaining the
pluripotency of hESC (54–56). Investigation of the BMP/
TGFb signalling pathways suggested that a large number of
the components of this pathway were present in undifferen-
tiated hESC, although some time at minimal levels
(Supplementary Material, Table S5). Like other researchers,
we found that NODAL and two of its inhibitors LEFTY1 and
LEFTY2 were expressed in human ESC, but they were
abruptly downregulated upon differentiation suggesting a
tight control of this signalling pathway in pluripotency
hESC (16,54). Interestingly, ALK5 that has been implicated
in the TGFb signalling is the only one among the ALKs
that show downregulation upon differentiation, thus providing
further support for the role of TGFb in maintaining the hESC
pluripotency as suggested by Amit et al. (3). Most interest-
ingly, two inhibitors of Activin A and BMP signalling,
FOLLISTATIN and BAMBI (BMP and Activin membrane
bound inhibitor) are greatly increased upon differentiation,
whereas a third inhibitor, CERBERUS, shows an abrupt
decrease upon differentiation. Vallier et al. (54) suggested
that Activin/Nodal pathway in co-operation with FGF2 is
necessary for the maintenance of pluripotency in hESC. Our
data does corroborate these findings. In spite of this, it high-
lights once more the complexity of these pathways and the
fine tune imposed not only by ligands and receptors, but
also by specific inhibitors.
MAPK/ERK, PI3/AKT and NFkb are important for
maintenance of pluripotency and viability in human ESC
To validate the importance of these signalling pathways
for maintenance of pluripotency and viability of hESC, we
used three inhibitors: Ly294002 (10 mM) which is a specific
PI3 kinase inhibitor already shown to interfere with the
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maintenance of pluripotency in mESC (57), U0126 (20
and 30 mM) a specific MEK1/2 inhibitor and sodium
pyrrolidinethiocarbamate (PTDC) (50 mM) a specific NFkb
inhibitor which prevents p65 entry into the nucleus. Inhibitors
concentration was chosen carefully based on the criteria of
inhibiting the chosen pathway without causing other non
specific effects. In the case of U0126, lower concentrations
(10 mM) did not result in inhibition of MAPK/ERK even
after 5–30 min of application. This could be due to the pre-
sence of FGF2 in the medium which activates ERK signalling
and counteracts the effects of U0126; therefore, higher
concentrations of this inhibitor (20–60 mM) were tested, 50
and 60 mM caused extensive cell death. Therefore, we selected
the lowest concentrations (20 and 30 mM) at which inhibition
of the MAPK/ERK signalling pathway was evident. The same
logic was applied for the NFkb inhibitor, although published
literature recommends a much higher effective concentration
(100 mM) compared with the other two inhibitors. We
noticed that at 50 mM concentration, the entry of p65 into
the nucleus was inhibited (Fig. 6H) and the effects on cell
differentiation and death were the same as when 100 mM
PTDC was applied; therefore, 50 mM PTDC was used in all
the following experiments.
Two to three days after the application of PTDC and
LY294002, cell differentiation was prominent in the middle
of hESC colonies compared with the control which was
vehicle alone (Fig. 6A). Cell differentiation was not evident
in the lower (20 mM) U0126 concentration (Fig. 6A);
however, this was observed as soon as the U0126 concen-
tration was increased to 30 mM (data not shown). In addition,
significant cell death was present when cells were treated with
U0126 and PTDC as assessed by Annexin V staining
(Fig. 6B). The increase in U0126 concentration also caused
an increase in total cell death which reached 62.6% at
30 mM. The amount of differentiation was assessed by alkaline
phosphatise staining (Fig. 6C), real-time RT–PCR analysis for
OCT4, NANOG and SOX2 (Fig. 6D) and flow cytometry for
SSEA-4 (Fig. 6E). In the case of LY294002 and PTDC, a sig-
nificant reductions in OCT4, NANOG and SOX2 expression
and AP staining and the percentage of SSEA-4-positive cells
(Fig. 6C–E) were observed, suggesting loss of pluripotency
upon inactivation of PI3K/AKT and NFkb signalling
pathways. This was also evident at the higher concentration
of U0126 (30 mM; Supplementary Material, Fig. S2A and B)
but not at the 20 mM concentration (Fig. 6B–E).
PI3K inactivation by LY294002 resulted as expected in
downregulation of the phosphorylated AKT kinase (both
serine 473 and threonine 308) and the downstream targets of
AKT kinase such as phosphorylated form of GSK3b and
c-RAF (serine 338; Fig. 6F and I). In addition, it resulted in
downregulation of several components of the MAPK/ERK
pathway such as the phosphorylated form of MEK1/2,
ERK1/2 and one of the intracellular effectors, phosphorylated
form of c-MYC (Fig. 6F and I). The active form of AKT has
been shown to directly phosphorylate and activate c-RAF (58)
(Fig. 5B), and from our results, it is obvious that inhibition
of the PI3/KAKT pathway results in downregulation of
the phosphorylated form of c-RAF (serine 338). Because
the active form of c-RAF phosphorylates MEK1/2, we are
inclined to speculate that the observed downregulation of the
other components of the MAPK/ERK signalling pathway
does not simply reflect the process of differentiation ongoing
in these cells but rather reflects a direct link between the
PI3K/AKT and MAPK/ERK pathway occurring at the level
of c-RAF (Fig. 7). Application of LY294002 also resulted in
reduction of phosphorylated form of p65; however, inhibition
of the NFkb pathway did not result in inactivation of the
PI3K/AKT pathway (Figs 6F, H, I and 7) suggesting that the
PI3K/AKT pathway acts upstream of the NFkb pathway. It
is widely reported in the literature that activated AKT kinase
phosphorylates Ikks, which serve as cytoplasmic sequestrators
of p65 and p50. Phosphorylation of Ikks results in their
ubiquitination and subsequent degradation (Fig. 5B) and
translocation of the activated p65/p50 complex into the
nucleus. Our initial results suggest that this is also likely to
be the case for hESC; however, further investigation into the
Ikks and their expression and function in hESC is required.
In several tumour cell lines, p65 expression has been
observed in both cytoplasm and nucleus, and activation of
the NFkb pathway is marked by translocation of the cyto-
plasmic form of p65 into the nucleus where together with
p50 it activates transcription of several genes. Immunocyto-
chemistry in both hESC cell lines indicated that p65 and
p50 are observed only in the nucleus (Fig. 5E). Application
of PTDC, a known inhibitor of the NFkb pathway, inhibits
the translocation of p65 to the nucleus and this is evident fol-
lowing addition of PTDC to hESC cultures where several
nuclei without p65 expression are duly observed (Fig. 6H).
As expected, no changes in p50 expression or localization
were observed. Downregulation of nuclear p65 expression
caused loss of viability as well as differentiation of hESC
highlighting the importance of NFkb pathway in the mainten-
ance of viability and pluripotency (Fig. 6A–E).
Inhibition of the MAPK/ERK signalling pathway by U0126
resulted as expected in decrease in the phosphorylated form of
ERK1/2 and one of its downstream effectors, the phosphory-
lated form of p90, RSK (Fig. 6G). It is worth mentioning
that no changes were observed in the expression of most of
the components of the PI3K/AKT pathway (phospho-AKT
serine 473 and threonine 308, phospho-PDK1, phospho-
GSK3b and phospho-c-RAF), whereas inhibition of PI3K/
AKT pathway resulted in downregulation of most of the
components of MAPK/ERK signalling cascade (Fig. 6F).
These results imply that MAPK/ERK signalling is down-
stream of the PI3K/AKT kinase. Inhibition of the MAPK/
ERK signalling at the level of MEK1/2 does not seem to
affect two of the components of the NFkb pathway
(Fig. 6G); however, inhibition of the NFkb pathway results
in downregulation of the activated form of ERK1/2 and its
downstream effector, p90 RSK (Fig. 6H and I), implying
that NFkb pathway acts upstream of the MAPK/ERK
signalling pathway. These results are summarized in a table
(Fig. 6I) and schematically outlined in Figure 7.
DISCUSSION
Elucidation of the signalling events that govern the self-
renewal and pluripotency of hESC is important for
understanding their physiology and devising optimal culture
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Figure 6.MAPK/ERK, PI3K/AKT and NFkb signalling is important for the maintenance of pluripotency and viability in hESC (hES-NCL1 is shown; however,
similar results were obtained with H1). (A) Photographs of hESC 4 days after the application of three inhibitors. (B) Viability of hESC after the application of
LY294002, U0126 and PTDC. (C) hESC pluripotency after application of LY294002, U0126 and PTDC measured by AP staining. (D) hESC pluripotency after
application of LY294002, U0126 and PTDC assessed by real-time RT–PCR for the expression of NANOG, OCT4 and SOX2. (E) Flow cytometry analysis for the
expression of SSEA4 after application of LY294002, U0126 and PTDC. (F) Flow cytometry analysis of the main components of PI3K/AKT kinase, MAPK/ERK
and NFkb signalling after the application of LY294002. (G) Flow cytometry analysis of the main components of PI3K/AKT kinase, MAPK/ERK and NFkb
signalling after the application of U0126. (H) Top panel: immunocytochemistry analysis for the expression of phospho-p65 and p50 in hESC after the application
of PTDC. Bright field images are shown in the left panels, antibody staining in the middle panels and cell nuclei staining by DAPI in the right-hand panels. The
white arrows indicate nuclei that have lost p65 expression. Bottom panel: flow cytometry analysis of the main components of PI3K/AKT kinase, MAPK/ERK
and NFkb signalling after the application of PTDC. (I) Summary of changes in expression of the main components of PI3K/AKT kinase, MAPK/ERK and NFkb
signalling pathways during differentiation of hESC to EBs and after the application of LY294002, PTDC and U0126.
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conditions for their large-scale growth. It is of equal import-
ance to understand the changes which take place in such
signalling networks as a cause or consequence of hESC differ-
entiation, as this may help us to devise better strategies to
direct differentiation into particular developmental pathways.
This will be of paramount importance to our efforts to
produce defined populations of cells for therapeutic use.
Transcription factors such as OCT4 (59) and NANOG (60)
are indispensable for the maintenance of pluripotency in
hESC but it has recently become evident that activation of
FGF2 signalling (61) or ERK activation (55) and its
co-operation with the Activin/Nodal signalling pathway (54)
are necessary to maintain the pluripotency of hESC. Substan-
tial differences exist in a number of key signalling pathways
between human and mouse ESC; for example, LIF/Stat3 and
Bmp4 signalling which are important for maintenance of
pluripotency in mESC do not play the same role in hESC
(12,13,61,62). In striking contrast to mESC which display
high ERK1/2 activity when they are stimulated to undergo
differentiation, hESC display high basal activity of ERK1/2
in the undifferentiated state which correlates with large
amounts of endogenous, high molecular mass FGF2 (63).
These fundamental differences highlight the need for new
and thorough signalling studies in hESC per se.
We undertook a large transcriptional study which was
focused on the molecular characterization of a new cell line
derived by our group from a day 8 blastocyst (hES-NCL1) and
highlighted important changes in gene expression during differ-
entiation to EBs. We identified an interesting phenomenon in
that the second largest group of transcripts downregulated
during differentiation of hESC were components of several
important signalling pathways, namely PI3K/AKT, RAS/
MAPK/ERK and NFkb signalling. Using a combination of
flow cytometry, western blotting and an antibody signalling
array, we confirmed that the majority of factors involved in
these signalling pathways and identified by our large-scale tran-
scriptional study were downregulated during the differentiation
of hESC, indicating a possible role in the maintenance of plur-
ipotency and viability in hESC. This hypothesiswas further con-
firmed by using specific inhibitors for each of the signalling
pathways (LY294002 for PI3K/AKT, U0126 for MAPK/ERK
and PTDC forNFkb)which caused loss of pluripotency and via-
bility at specific concentrations. These results are not entirely
surprising given the contribution of the aforementioned signal-
ling pathways in a number of human cancers (64) and during
embryogenesis (65–67).
A number of studies conducted in mouse embryos have
shown that most of the MAPK/ERK pathway proteins were
present in trophoblast and the inner cell mass at embryonic
day 3.5, where they may mediate mitogenic signals within the
embryo or coming from the uterus (65). Most importantly,
knockouts of FRS2a, Gab1, Grb2, Sos-1, Raf-B and Raf1
result in peri-implantation or placental lethality (66) and this
could well be due to defects in formation of placental tropho-
blasts given the role of Ras in extraembryonic endoderm differ-
entiation (67). In this context, it worth mentioning two main
differences between the human and the murine system that
can help with further interpretation of our results. First, in
mouse, FGF/MAPK signalling seems to be involved in
trophoblast and thus placental development (68,69), whereas
in the humans, relatively high and stable concentration of
FGF2 is needed to maintain the proliferation and pluripotency
of hESC (61). Secondly, in the murine system, the suppression
of MAPK/ERK signalling by BMP4 promotes the self-
renewal of mESC and aids their derivation (70–72), whereas
in the human, addition of BMP4 causes differentiation of
hESC to trophoectoderm (13). This suggests a different role
for MAPK/ERK signalling in hESC and our results show that
this is indeed the case. We observed significant cell death in
hESC cultures treated with 20 mM of MEK1/2 inhibitor
(U0126) and this increased with increasing concentrations of
inhibitor. No prominent loss of hESC morphology and pluripo-
tency was observed at the 20 mM concentration of U1026,
whereas an increase in U0126 concentration to 30 mM caused
cell differentiation as described in our Results and Supplemen-
taryMaterial, Figure S2.While this manuscript was under prep-
aration, two reports described the dosage-dependent effect of
FGF2 on hESC renewal (61) and ERK activation by FGF2 in
hESC (55) and this perhaps explains the dosage-dependent
effects of U0126. Interestingly, in the murine system, the ortho-
logue of the human ERAS gene plays an important role in the
proliferation of mESC; however, this gene does not bind to
Raf or activate the MAPK cascade (73). This together with
our data would suggest that other RAS family components
such as K-RAS and H-RAS, also enriched in hESC compared
to EBs (56) (Supplementary Material, Table S5), or other
downstream components of the MAPK cascade activate
MAPK/ERK in hESC more than in the differentiated cells of
the EBs. Although these biochemical assays remain to be
carried out in hESC, our results strongly suggest an efficient
Figure 7. Schematic presentation of likely signalling events in hESC. FGF2
has been shown to maintain hESC pluripotency by activating MAPK/ERK sig-
nalling pathways (this is indicated by uninterrupted lines). Our own data
suggest that MAPK/ERK and NFkb act downstream of the PI3K/AKT
pathway and these three pathways are important for maintenance of the undif-
ferentiated state and viability (this is indicated by interrupted lines). A possible
link between FGF2 and subsequent activation of PI3K/AKT pathway that is
not proven as yet is indicated by a question mark.
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downregulation of several important components of the
MAPK/ERK cascade during hESC differentiation at both tran-
scriptional and translational/post-translational level and a
crucial role for the MAPK/ERK activation in hESC.
Extensive work in mESC has suggested that the PI3K
pathway plays an important role in proliferation, tumourigeni-
city and maintenance of the undifferentiated state (reviewed in
74). We found that most of the active components of the PI3K/
AKT pathway such as the phosphorylated form of AKT and
PDK1 are downregulated during hESC differentiation to EBs
and inactivation of this pathway results in differentiation. In
addition, we observed a downregulation in the active
components of the MAPK/ERK and NFkb pathways,
whereas inactivation of these in isolation did not disrupt
those of the PI3K/AKT pathway suggesting that MAPK/
ERK and NFkb act downstream of the PI3K/AKT kinase.
This is not completely unexpected or surprising. Current
literature suggests that in other human cell types, AKT and
PDK1 phosphorylate Ikks (52,53), which serve as cytoplasmic
sequestrators of p65 and p50. Phosphorylation of Ikks results
in their ubiquitination and subsequent degradation and trans-
location of the activated p65/p50 complex into the nucleus
which initiates NFkb-dependent transcription; therefore,
high activity of PI3K/AKT would be reflected in a more
active NFkb signalling. Our results support a role for PI3K/
AKT-dependent activation of the NFkb signalling cascade
in maintenance of viability and the undifferentiated state in
hESC. Activation of the MAPK/ERK pathway by PI3K/
AKT has also been documented in several other stem cells
(murine haematopoietic stem cells (75) and germ cells
(Xenopus oocytes) (76), and although the mechanisms
involved are not fully understood, our data and others point
to PI3K/AKT-dependent MAPK/ERK activation at some
point between RAS and MEK1/2. However, further work is
needed to verify this hypothesis.
It is interesting that FGF2 has been suggested to act via
activation of the MAPK/ERK pathway (55,63). Our results
highlight that MAPK/ERK and NFkb signalling are likely to
act downstream of the PI3K/AKT pathway and that the
majority of the active components of the three signalling
pathways are downregulated during hESC differentiation to
EBs which takes place in the absence of FGF2. This raises
an intriguing possibility that FGF2 initiates a hierarchical sig-
nalling cascade (outlined in Fig. 7) with sequential activation
of PI3K/AKT, MAPK/ERK and NFkb cascades. If this is the
case, monolayer differentiation in the absence of FGF2 should
result in similar downregulation of the active components of
these pathways and our own preliminary data indicate that
this is indeed the case (Armstrong and Lako, unpublished
data). Our inhibitor study was conducted in the presence of
FGF2; however, if the above hypothesis is true, one would
expect more dramatic effects if inhibition of these signalling
pathways was carried out in the absence of FGF2. This
work is currently in progress within our group.
Our results suggest that activation of the MAPK/ERK is
important for the maintenance of viability in hESC and this
is dependent on the activation of the NFkb cascade, already
shown to govern cell survival and play a similar role in
many human cancer cell types (77,78). This raises intriguing
questions as to whether the mechanisms involved in mainten-
ance of the undifferentiated state and viability in hESC are
similar to the ones observed in cancer cells. This may help
to understand some of the mechanisms involved in karyotypic
abnormalities observed in ‘culture-adapted hESC’, which
result in clonal selection and escape from FGF2-dependent
signalling (79,80).
A detailed molecular and functional characterization of all
the cell lines derived by different labs at various stages of
embryonic development, in view of the differences in their
ability to differentiate in vitro to different lineages observed
by us and others, is essential for our understanding of hESC
biology (14,18,22,23). Our transcriptional study of a well-
characterized cell line derived from day 8 embryos,
hES-NCL1 (25), has shown that the developmental stage
from which the cell line is derived does not enhance the mol-
ecular differences between different cell lines that are more
likely to result from their different genetic profile. We have
used these data to isolate new cell surface markers such as
transferrin receptor (TFRC) that can be used to separate
hESC from differentiated cells. We were unable to identify
any other novel cell surface markers specific for hESC;
however, we are currently performing bioinformatic analysis
on the uncharacterized and novel transcripts which comprised
33.6% of the genes we identified to be enriched in hES-NCL1.
Our study for the first time has used flow cytometry analysis
to characterize a large number of components involved in
three signalling pathways. The validity of the method is
supported by other techniques such as western blotting and
antibody arrays. Using these techniques, we have added new
intracellular markers which can be used to compare hESCs
with differentiated progeny. This knowledge can now be
used to aid definition of GMP-compatible media for
large-scale growth of hESC. Examples of this approach
already exist; for example, g-aminobutyric acid and pipecolic
acid have been used in defined hESC medium to derive new
stem cell lines based on enhanced expression of GABA A
receptor subunit beta 3 (42) in hESC. Interestingly, we have
shown in this manuscript that the transferrin receptor is
enriched in hESC compared with EBs. Not surprisingly, trans-
ferrin is used in other hESC defined media (54). On a similar
note, small molecules that activate PI3K/AKT, MAPK/ERK
and NFkb cascades can be investigated for this purpose.
Similarly, small molecules that inhibit the specific pathways
can also be explored for setting off specific differentiation
pathways in hESC.
Understanding how the specification events occur in the
human pre-implantation embryos has been difficult to dissect
in humans given the lack of sufficient embryonic material.
On this basis, we feel that our functional investigation of
signalling pathways in hESC will shed some light on the
biological events during pre-implantation development and
will help with new methods to derive embryonic stem cell
lines suitable for clinical purposes.
MATERIALS AND METHODS
Culture and differentiation of hESC
Human ESC were grown on mitotically inactivated mouse
embryonic fibroblasts with hESC medium containing
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Knockout-DMEM (Invitrogen, Paisley, UK), 100 mM
b-mercaptoethanol (Sigma, Dorset, UK), 1 mM L-glutamine
(Invitrogen), 100 mM non-essential amino acids (Invitrogen),
20% serum replacement (SR, Invitrogen), 1% penicillin–
streptomycin (Sigma) and 8 ng/ml FGF2 (Invitrogen). hESC
medium was changed daily. hESC were passaged by incu-
bation in 1 mg/ml collagenase IV (Invitrogen) for 5–8 min
at 378C or mechanically dissociated and then removed to
freshly prepared feeders. EB differentiation was induced by
harvesting hESC with collagenase as described above and
culturing them in suspension in Knockout DMEM medium
(Invitrogen) containing 20% fetal calf serum (FCS)
(Hyclone), 1 mM L-glutamine (Invitrogen), 100 mM non-
essential amino acids (Invitrogen), 100 mM b-mercaptoethanol
(Sigma) and 1% penicillin–streptomycin (Sigma).
Karyotype analysis of hESC
The karyotype of hESC was determined by standard
G-banding procedure.
Flow cytometry analysis of hESC
For the flow cytometry analysis, the hESC were collected
using collagenase IV treatment (1 mg/ml for 5 min) followed
by brief accutase incubation (Chemicon). hESC were
suspended in staining buffer [phosphate-buffered saline
(PBS) þ5% FCS] at concentration of 106 cells/ml. About
105 cells were stained with TRA1-60, TRA1-81, SSEA-3,
SSEA-4 (10 mg/ml final concentration, Chemicon), CD117
and CD135 (10 mg/ml final concentration, BD Biosciences,
Oxford, UK). Several washes were carried out in staining
buffer before proceeding to staining with secondary anti-
bodies (goat anti-mouse IgG/M conjugated to FITC). Intra-
cellular staining was performed by fixing the cells for
10 min in 0.5% formaldehyde followed by gentle permeabi-
lization in ice-cold 90% methanol. The permeabilized cells
were washed three times in staining buffer before being
stained with the primary antibodies for 30 min at room
temperature. The primary antibodies were purchased from
Cell Signaling Technologies as part of the phospho-
Akt pathway sampler kit (phospho-AKT-serine 473,
phospho-AKT-threonine 308, AKT, phospho-GSK3b-serine
9, phospho-c-RAF-serine 259, phospho-PTEN-serine 380
and phospho-PDK1-serine 241) or phospho-ERK1/2
pathway sampler kit (phospho-c-RAF serine 338, phospho-
MEK1/2 serine 217/221, phospho-ERK1/2-threonine 202/
tyrosine 204, phospho-p90 RSK-serine 380, phospho-ELK-1
serine 383) or as separate unconjugated antibodies
(phospho-c-MYC threonine 58/serine 62, phospho-p65
serine 536). The other antibodies were purchased from
R&D systems (TFRC, PTEN), Abcam (GABA A receptor
beta3, GPR64, phospho-NFkb p50 serine 529), Santa
Cruz Biotechnology Inc. (GALECTIN-1, phospho-FRS2/
tyrosine 436, GRB2/C-23, Sos1/H-122, GAB1/H-198 and
phospho-c-RAF serine 338) and Chemicon (LCK, TNFS11/
RANKL). All antibodies were used at concentrations
suggested by the manufacturers unless otherwise stated.
Three washes in staining buffer were carried out before
staining with secondary antibody, goat anti-mouse
IgM/G-FITC (6 mg/ml final concentration; Sigma) or
donkey anti-rabbit IgM/G-FITC (6 mg/ml final concentration;
Sigma). Cells were washed again three times and resus-
pended in staining buffer before being analysed with FACS
Calibur (BD) using the CellQuest software. Ten thousand
events were acquired for each sample and propidium
iodide staining (1 mg/ml) was used to distinguish live from
dead cells for extracellular markers.
Immunostaining and fluorescence microscopy
Cells were fixed with 4% paraformaldehyde for 10 min and
permeabilized with 0.1% Triton X-100 and 5% FCS in PBS
at room temperature for 45 min. The cells were incubated at
room temperature for 17 h with the primary antibodies
described earlier (1:100 dilution) and subsequently washed
with 5% FCS and PBS before addition of the appropriate
secondary antibody (Rhodamine-conjugated anti-goat IgG
from Jackson ImmunoResearch, 1:100, was used to detect
phospho-c-RAF serine 338 purchased from Santa Cruz,
whereas for the rest FITC-conjugated anti-rabbit immuno-
globulins from Sigma-Aldrich, 1:100, were applied). The
cells were washed before fluorescence microscopy and the
images were collected using a Zeiss microscope and Axiovert
software.
Western blotting
Cell lysates were electrophoresed on a 10% SDS–PAGE gel
and electrophoretically transferred to a polyvinylidene difluor-
ide membrane (Hybond-P, Amersham). Membranes were
blocked in Tris-buffered saline with 5% milk and 0.1%
Tween. The blots were probed with phospho-ERK1/2 kinase
(Cell Signaling Technology, 1:1000), phospho-p90 RSK (Cell
Signaling Technology, 1:1000), phospho-MEK1/2 (Cell
Signaling Technology, 1:1000), GAPDH (Abcam, 1:2000)
overnight and revealed with horseradish peroxidase-conjugated
secondary anti-rabbit antibody (Amersham Biosciences,
1:20 000). Antibody/antigen complexes were detected using
ECL reagent (Amersham Biosciences) and GeneSnap software
(version 4.00.00, SYNGENE) with GeneGnome (SYNGENE).
Bands were analysed using the GeneTools software (version
3.00.22, SYNGENE).
Inhibitor studies
MEK1/2 inhibitor (U0126), PI3K inhibitor (LY2940002) and
NFkb inhibitor (PTDC) were purchased from Sigma. The
hESC were plated in matrigel in the presence of MEF
conditioned medium as described in Stojkovic et al. (25).
Inhibitors were added the following day and medium was
changed every day for the following 6 days of culture. The
choice of inhibitors concentration (10 mM for LY2940002,
20 and 30 mM for U0126 and 50 mM for PTDC) was based
on other published reports for mESC and our empirical trials.
Cell signalling assays
Panorama Ab microarray for cell signalling containing 224
different antibodies spotted in duplicate on nitrocellulose-
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coated glass were purchased from Sigma. One milligram of
hESC (H1 and hES-NCL1) and EB cell extracts was collected,
labelled with Cy3 and Cy5, respectively, and hybridized to the
slides according to manufacturer’s instructions. Dye reversal
experiments were also carried out for the hES-NCL1. Cy3
and Cy5 signals were read on Gene Pix Pro 4.0 and norma-
lization in each case was carried out using as reference
the beta-actin house keeping protein included in the
chip. The hESC/EB ratio was calculated using MS Excel.
A ratio .1.0 indicates higher expression in hESC than EBs
and ratio ,1.0 indicates higher expression in EBs compared
with hESC.
Microarray analysis
Total RNA was extracted from hESC and EBs at days 6, 10,
14 and 21 using Trizol (Invitrogen), and 10 mg of the RNA
sample was used to make biotin-labelled cRNA (copy RNA)
according to manufacturer’s instructions. Following appropri-
ate clean-up of the cRNA (IVT cRNA clean-up spin column
as supplied with Affymetrix gene chips), biotin-labelled
cRNA was quantified and fragmented by metal-induced
hydrolysis according to manufacturer’s protocol (Affymetrix,
Buckinghamshire, UK). This converts full-length cRNA into
fragments of 35–200 bp in length which are suitable for
hybridization. Prior to hybridization, a test array of house-
keeping controls was analysed to determine sample suitability
for GeneChip arrays. Biotin-labelled cRNAs produced in this
manner were hybridized to the Human U133 Plus 2 array and
washed according to manufacturer’s protocol. The MAS 5.0
software detection algorithm (Affymetrix) was used to deter-
mine the presence (P), absence (A) or marginal expression
(M) of each gene in the array. The data obtained from MAS
5.0 were then normalized and further analysed in the
GeneSpring software 6.2 (Silicon Genetics). Per chip normal-
ization was done as follows. Values below 0.01 were set to
0.01 and then each measurement was divided by the 50th
percentile of all measurement in that sample. A gene was
nominated as differentially expressed between the two cell
lines if change call was increased or decreased and the
change P-value was ,0.05. A gene was defined as signifi-
cantly upregulated if the signal fold change (FC) between
the target and reference sample was larger than 2 and the
target sample was present. Alternatively, a gene was defined
as significantly downregulated if the FC was less than 22
and the reference sample was present. As suggested by the
manufacturer, the probe sets were excluded if the detection
call for both the target and the reference were ‘absent’ or if
no change call (NC) was detected (NC, change P . 0.05).
Only the genes that fulfilled all the filtering criteria reproduci-
bly in three biological replicates were considered significant.
In testing for the reproducibility of the samples (H1 and
hES-NCL1), correlation coefficients of the normalized signal
intensities of the replicate samples were calculated. These
calculations were performed automatically in MS Excel
using Pearson’s correlation coefficient formula (given
subsequently). The signal intensity values from the samples
were pasted into an MS Excel spreadsheet. The statistical
function CORREL was chosen from the functions wizard,
the values from the samples to be compared were selected
and finally the correlation coefficient of the two samples
being compared was presented.
r ¼ SXY  ðSXSY=N Þffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
ðSX 2  ðSX Þ2=N ÞðSY 2  ðSY Þ2=N Þ
p
Where X is the normalized signal intensities from H1, Y the
normalized signal intensities from hES-NCL1 and N the
number of normalized signal intensities in each sample.
RT–PCR analysis
RT was carried out using the cells of cDNA II kit (Ambion,
Huntingdon, UK) according to manufacturer’s instructions.
In brief, hESC were submerged in 100 ml of ice-cold cell
lysis buffer and lysed by incubation at 758C for 10 min.
Genomic DNA was degraded by incubation with DNAse I
for 15 min at 378C. RNA was reverse transcribed using
M-MLV reverse transcriptase and random hexamers following
manufacturer’s instructions. PCR reactions were carried out
using the following primers:
OCT4F: 50-GAAGCTGGAGAAGGAGAAGCTG-30;
OCT4R: 50-CAAGGGCCGCAGCTTACACATGTTC-30;
REX1F: 50-GCGTACGCAAATTAAAGTCCAGA-30;
REX1R: 50-CAGCATCCTAAACAGCTCGCAGAAT-30;
NANOGF: 50-GATCGGGCCCGCCACCATGAGTGTGGAT
CCAGCTTG-30;
NANOGR: 50-GATCGAGCTCCATCTTCACACGTCTTCAG
GTTG-30;
TERTF: 50-CGGAAGAGTGTCTGGAGCAAGT-30;
TERTR: 50-GAACAGTGCCTTCACCCTCGA-30;
GAPDHF: 50-GTCAGTGGTGGACCTGACCT-30;
GAPDHR: 50-CACCACCCTGTTGCTGTAGC-30.
PCR products were run on 2% agarose gels and stained with
Ethidium bromide. Results were assessed on the presence or
absence of the appropriate size PCR products. Reverse
transcriptase negative controls were included to monitor
genomic contamination.
LightCycler real-time PCR analysis
Real-time PCR analysis was carried out using QuantiTect
SYBR Green PCR Master mix (Qiagen). The reaction was
performed with 1 ml cDNA per 20 ml reaction and each reac-
tion was performed in triplicate. The LightCycler experimen-
tal run protocol used was: PCR activation step (958C for
15 min), amplification with data acquisition repeated 50
times (948C for 15 s, annealing temperature for primers for
30 s, 728C for 20 s with a single fluorescence data collection),
melting curve (60–958C with a temperature transition rate of
0.18C/s and continuous fluorescence data collection) and
finally cooling to 408C. The crossing point (CP) for each tran-
script was determined using second derivative maximum
method in the LightCycler software v3.5.3 (Roche Diagnos-
tics). GAPDH CP for each sample was used as the internal
control of these real-time analyses. The data were analysed
using the LightCycler relative quantification software v1.01
(Roche Diagnostics). For each gene, the value for the hESC
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was set to 1 (100%) and all other values were calculated with
respect to this. Statistical significance of the results was
assessed using Student’s t-test (P , 0.05). PCR reactions
were carried out using the following primers:
GDF3F: 50-GTCCGCGGGAATGTACTTCG-30;
GDF3R: 50-CACCTTGTGGCCATGGGACT-30;
NANOGF: 50-AGAAGGCCTCAGCACCTAC-30;
NANOGR: 50-GGCCTGATTGTTCCAGGATT-30;
OCT4F: 50-TCTCGCCCCCTCCAGGT-30;
OCT4R: 50-GCCCCACTCCAACCTGG-30;
SOX2F: 50-GGCAGCTACAGCATGATGCAGGAGC-30;
SOX2R: 50-CTGGTCATGGAGTTGTACTGCAGG-30;
AFPF: 50-TGCAGCCAAAGTGAAGAGGGAA-30;
AFPR: 50-ATAGCGAGCAGCCCAAAGAAGA-30;
KDRF: 50-CAGACGGACAGTGGTATGGT-30;
KDRR: 50-AGCCCAGATTCTCCAGCCTG-30;
PDCD6F: 50-CGGACCAGAGCTTCCTGTGG-30;
PDCD6R: 50-ACACACCCGTGAACTCGCTG-30;
ZNF224F: 50-TCGTAGCCATCACGGAGCTG-30;
ZNF224R: 50-ACCCAGGGCATCAGCTTCTG-30;
GAPDHF: 50-GTCAGTGGTGGACCTGACCT-30;
GAPDHR: 50-CACCACCCTGTTGCTGTAGC-30;
SLC1A6F: 50-CTGCAGCATCACGGCCACAG-30;
SLC1A6R: 50-CCGTCCCCGGGATGCCCCCT-30;
TXNRD3F: 50-ACTTTGTTCTGGCCTCTTGA-30;
TXNRD3R: 50-GTGAATTCCAATGGTGTCAT-30;
XRCC4F: 50-TTCAAGTCTTGATGTCACTG-30;
XRCC4R: 50-TTCTAAAGACATGTTTTCAG-30;
MNS1F: 50-CAGTTGCAGCAAAGGCGGCA-30;
MNS1R: 50-GTAATCCCAGCTACTCAGGA-30;
ZNF441F: 50-AAGGCTGGGTATGGTGGCTC-30;
ZNF441R: 50-GTAAAGGGTCCTCCACATTG-30;
GSST1F: 50-GTCCTCACATCTCCTTAGCT-30;
GSST1R: 50-CATGGGCCTCCTGGAAGAGG-30;
PCDHB6F: 50-GGTCGCTACTCGGTGCCCGA-30;
PCDHB6R: 50-TCATATTGTCAAGTACCCTC-30;
PAX6F: 50-GAATCAGAGAAGACAGGCCA-30;
PAX6R: 50-CGCCTGGATATGCGCCAGCT-30.
Population doubling time assays
Human ESC colonies were harvested by collagenase treatment
and subjected to accutase digest for 2 min at room tempera-
ture. Live cells were counted using Trypan blue (Sigma)
exclusion. Fifty thousand live cells were added to each well
of a four-well plate containing mitotically inactivated mouse
embryonic fibroblasts and 0.5 ml of human ESC medium
with basic fibroblast growth factor. Cells were permitted to
grow for 5 days and cell numbers were estimated using
Trypan blue exclusion method. The number of population
doublings was estimated as PD ¼ ln(n2/n1)/ln 2, where n1
was the seeded cell amount and n2 the obtained cell amount.
Apoptosis assay
Cells undergoing apoptosis can be enumerated using the
Annexin V-FITC apoptosis detection kit (BD Biosciences-
Pharmingen) in which FITC-conjugated Annexin V binds to
the externalized phosphatidyl serine characteristic of apoptotic
cells. The protocol was carried out in accordance with
manufacturer’s instructions and briefly comprises the
following. Cells were harvested using accutase, washed
twice with ice-cold PBS and counted. 1  105 cells are
suspended in 100 ml of 1  binding buffer (supplied), then
5 ml of Annexin V-FITC and 5 ml of propidium iodide
solution are added. The mixture is vortexed gently and
incubated for 15 min at room temperature in the dark. About
400 ml 1  binding buffer is added and the cells are analysed
by flow cytometry (FACS Caliber, Becton Dickinson).
AP staining
AP staining was carried out using the Alkaline Phosphatase
Detection Kit following manufacturer’s instructions (Chemi-
con, Temecula, CA, USA; www.chemicon.com). Briefly
cells were fixed in 90% methanol and 10% formamide for
2 min and then washed with rinse buffer (20 mM Tris–HCl
pH 7.4, 0.05% Tween-20) once. Staining solution (Naphthol/
Fast Red Violet) was added to the wells, and plates were incu-
bated in the dark for 15 min. The bright field images were
obtained using a Zeiss microscope and AxioVision software
(Carl Zeiss, Jena, Germany).
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG Online.
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